{"id":248,"date":"2023-02-20T10:02:56","date_gmt":"2023-02-20T10:02:56","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=248"},"modified":"2023-04-17T14:06:24","modified_gmt":"2023-04-17T13:06:24","slug":"pace-nodes","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=248","title":{"rendered":"Pace-Nodes"},"content":{"rendered":"\n

A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

PACE-NODES aims to compare prostate and pelvic nodal SBRT (PPN-SBRT) with prostate alone SBRT (P-SBRT) to determine whether PPN-SBRT has superior biochemical\/clinical-failure free rate (reduces the risk of biochemical or clinical failure by 50% or more) than P-SBRT, in patients with high risk localised prostate cancer.  536 patients will be recruited from 25-30 UK and international sites over 2.5 years.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>Streamlined<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>Streamlined<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>PPN-SBRT case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>1 for each trial arm<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>PACE, PEARLS and PIVOTALboost trials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact: <\/strong>pace-nodes.rtqa@nhs.net <\/p>\n\n\n\n

Chief investigator: <\/strong>Professor Nicholas van As<\/p>\n\n\n\n

Co-clinical leads: <\/strong>Dr Angela Pathmanathan and Professor Suneil Jain<\/p>\n\n\n\n

Sponsor: <\/strong>The Institute of Cancer Research (pace-nodes-icrctsu@icr.ac.uk)<\/p>\n\n\n\n

Funder: <\/strong>Prostate Cancer UK (PCUK)<\/p>\n","protected":false},"excerpt":{"rendered":"

A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT Trial summary: PACE-NODES aims […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-248","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=248"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/248\/revisions"}],"predecessor-version":[{"id":363,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/248\/revisions\/363"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}